NASDAQ:NTLA

Intellia Therapeutics Stock Insider Trading

etoro logo Buy NTLA
*Your capital is at risk
$12.02
+0.0800 (+0.670%)
At Close: Aug 10, 2026

Intellia Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 28.88. In total, the insiders bought 2.22M and sold 222.41K NTLA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
28.88
Buy 2.22M shares
Sell 222.41K shares
68% Buy Activity
Weak Negative Correlation
Sell Signal Low Confidence
Jul 22, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 28.88.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Mar 01, 2026
Buy
Stock Option (right to buy)
A-Award
Basta James
EVP, General Counsel
Officer 65 829
Value: $907.1K
Mar 01, 2026
Buy
Common Stock
A-Award
Lebwohl David
EVP, Chief Medical Officer
Officer 9 943
Value: $119.5K
Mar 01, 2026
Buy
Stock Option (right to buy)
A-Award
Dulac Edward J Iii
EVP, Chief Financial Officer
C-Suite Officer 87 543
Value: $1.21M
Mar 01, 2026
Buy
Stock Option (right to buy)
A-Award
Schultes Birgit C
EVP, Chief Scientific Officer
Officer 56 000
Value: $771.7K
Mar 01, 2026
Buy
Common Stock
A-Award
Clark Eliana
EVP, Chief Technical Officer
Officer 7 353
Value: $88.4K
Mar 01, 2026
Buy
Stock Option (right to buy)
A-Award
Clark Eliana
EVP, Chief Technical Officer
Officer 10 505
Value: $144.8K
Mar 01, 2026
Buy
Common Stock
A-Award
Dube Michael P
Vp, Chief Accounting Officer
Officer 17 250
Value: $207.3K
Jan 05, 2026
Sell
Common Stock
S-Sale
Dube Michael P
Vp, Chief Accounting Officer
Officer 2 989
Value: $27.5K
Jan 05, 2026
Sell
Common Stock
S-Sale
Dulac Edward J Iii
EVP, Chief Financial Officer
C-Suite Officer 6 379
Value: $58.8K
Jan 05, 2026
Sell
Common Stock
S-Sale
Clark Eliana
EVP, Chief Technical Officer
Officer 9 515
Value: $87.6K
Jan 05, 2026
Sell
Common Stock
S-Sale
Lebwohl David
EVP, Chief Medical Officer
Officer 11 903
Value: $109.6K
Jan 05, 2026
Buy
Common Stock
P-Purchase
Cohen Fred E
Director
Director 150 000
Value: $1.40M
Jan 05, 2026
Sell
Common Stock
S-Sale
Basta James
EVP, General Counsel
Officer 10 397
Value: $95.8K
Jan 05, 2026
Sell
Common Stock
S-Sale
Schultes Birgit C
EVP, Chief Scientific Officer
Officer 8 508
Value: $78.4K
Jan 05, 2026
Sell
Common Stock
S-Sale
Leonard John M
President And CEO
CEO / President 34 146
Value: $314.5K
Dec 12, 2025
Buy
Stock Option (right to buy)
M-Exempt
Leonard John M
President And CEO
CEO / President 8 557
Value: $58.4K
Dec 12, 2025
Buy
Common Stock
M-Exempt
Leonard John M
President And CEO
CEO / President 8 557
Value: $58.4K
Dec 11, 2025
Buy
Common Stock
M-Exempt
Leonard John M
President And CEO
CEO / President 49 959
Value: $341.2K
Dec 11, 2025
Sell
Common Stock
S-Sale
Leonard John M
President And CEO
CEO / President 49 959
Value: $474.1K
Dec 11, 2025
Sell
Common Stock
S-Sale
Leonard John M
President And CEO
CEO / President 32 832
Value: $310.9K
Dec 11, 2025
Sell
Common Stock
S-Sale
Leonard John M
President And CEO
CEO / President 5 355
Value: $51.4K
Dec 11, 2025
Buy
Stock Option (right to buy)
M-Exempt
Leonard John M
President And CEO
CEO / President 49 959
Value: $341.2K
Oct 01, 2025
Sell
Common Stock
S-Sale
Schultes Birgit C
EVP, Chief Scientific Officer
Officer 31
Value: $539
Oct 01, 2025
Sell
Common Stock
S-Sale
Dube Michael P
Vp, Chief Accounting Officer
Officer 1 871
Value: $32.5K
Oct 01, 2025
Sell
Common Stock
S-Sale
Dube Michael P
Vp, Chief Accounting Officer
Officer 1 871
Value: $32.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT INTELLIA THERAPEUTICS INC
Intellia Therapeutics
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline...
GOLDEN STAR
Ticker Change Signal Date
GPOR
$158.45
6.03% Aug 06
FCX
$62.63
12.61% Jul 31
BIIB
$202.19
2.44% Jul 24
TSCO
$30.32
14.18% Jul 23
S
SW
$43.71
8.88% Jul 23

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE